logo
Impact Radar
  • Overview
  • Impact Performance
  • Compare this company
  • All sources
    • Sign UpLog In
    logo

    Dermapharm | Sustainability & Chart

    DE000A2GS5D8

    Basic information on Dermapharm

    Location: Germany

    Industry: Manufacturing

    Website

    knob-globe
    41%

    Impact Score

    Description Dermapharm

    Dermapharm is a German pharmaceutical company focusing on the manufacturing and distribution of patent-free drugs and health products.

    Dermapharm Sustainability Performance

    Renewable Energy
    Greenhouse Gas Emissions
    Supply Chain
    Waste Recycling
    Sustainable [100]
    Almost sustainable [67-99]
    Moderate [34-66]
    Not sustainable [0-33]
    No data
    We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.

    Compare Dermapharm with ...

    Dermapharm

    ?

    Impact Score

    knob-globe
    41%
    knob-globe
    0%
    Climate
    Society
    Gender

    Sources of sustainability performance

    MetricValueUnitYearPDF NamePDF Page
    CEO-to-Employee Pay Ratio
    CEO salary1 416EUR thousand2024DERMAPHARM_FY_2024_ANNUAL_REPORT.pdf171
    Number of employees3 610number2024DERMAPHARM_FY_2024_ANNUAL_REPORT.pdf135
    CEO nameDr. Hans-Georg Feldmeier2024DERMAPHARM_FY_2024_ANNUAL_REPORT.pdf152
    Total wages paid279 799EUR thousand2024DERMAPHARM_FY_2024_ANNUAL_REPORT.pdf135
    Employee turnover rate
    Employee turnover10,28rate2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf37
    Glass Ceiling
    Women in workforce2 113Female2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf36
    Number of employees3 610number2024DERMAPHARM_FY_2024_ANNUAL_REPORT.pdf135
    Harassment and Discrimination at the Workplace
    Incident notification mechanismYes2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf35
    Anti-discrimination policyYes2024DERMAPHARM_FY_2024_ANNUAL_REPORT.pdf60
    Retaliation safeguardsYes2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf48
    Confidentiality mechanismsYes2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf48
    Women on the Board
    Executive board size3Board2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf7
    Supervisory board size3members2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf8
    Women on executive board0Board2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf7
    Women on supervisory board0members2024Dermapharm_SeparateNonfinancialGroupReport-2024_en_mLinks_locked.pdf8
    Women in Management
    Women in management50%2024DERMAPHARM_FY_2024_ANNUAL_REPORT.pdf12
    Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.

    Find more sustainable companies

    logo
    HomeFind Companies & ETFsLearn to investAcademyGlossaryOur Method
    ImprintPrivacy PolicyGTCFAQContact Us
    © 2025 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The source of ETF data is the websites and data sheets of the respective ETF providers.Logos provided by Clearbit (https://clearbit.com/). All trademarks and logos appearing on this website are the property of their respective owners and are used here for informational and educational purposes only, under fair use guidelines. We claim no affiliation with, nor endorsement by, the companies whose trademarks and logos are displayed. This website is independent of the brands analyzed and receives no direct or indirect compensation from them.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support!